School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
Kristy Hamilton
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
Rachel Milligan
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
Olivia Pearce
Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, United Kingdom
Lea Knezevic
Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
Begonia Morales Aza
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
Alice Milne
Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
Emily Milodowski
Bristol Veterinary School, University of Bristol, Bristol, United Kingdom
Eben Jones
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
Rajeka Lazarus
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
Anu Goenka
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom
Adam Finn
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United Kingdom; School of Population Health Sciences, University of Bristol, Bristol, United Kingdom
Nicholas Maskell
Academic Respiratory Unit, North Bristol NHS Trust, Bristol, United Kingdom
Coronavirus disease-19 (COVID-19) causes immune perturbations which may persist long term, and patients frequently report ongoing symptoms for months after recovery. We assessed immune activation at 3–12 months post hospital admission in 187 samples from 63 patients with mild, moderate, or severe disease and investigated whether it associates with long COVID. At 3 months, patients with severe disease displayed persistent activation of CD4+ and CD8+ T-cells, based on expression of HLA-DR, CD38, Ki67, and granzyme B, and elevated plasma levels of interleukin-4 (IL-4), IL-7, IL-17, and tumor necrosis factor-alpha (TNF-α) compared to mild and/or moderate patients. Plasma from severe patients at 3 months caused T-cells from healthy donors to upregulate IL-15Rα, suggesting that plasma factors in severe patients may increase T-cell responsiveness to IL-15-driven bystander activation. Patients with severe disease reported a higher number of long COVID symptoms which did not however correlate with cellular immune activation/pro-inflammatory cytokines after adjusting for age, sex, and disease severity. Our data suggests that long COVID and persistent immune activation may correlate independently with severe disease.